ECSP10010153A - Composiciones farmacéuticas que contienen antagonistas de bradiquinina y ácido hialurónico y sus usos - Google Patents
Composiciones farmacéuticas que contienen antagonistas de bradiquinina y ácido hialurónico y sus usosInfo
- Publication number
- ECSP10010153A ECSP10010153A EC2010010153A ECSP10010153A ECSP10010153A EC SP10010153 A ECSP10010153 A EC SP10010153A EC 2010010153 A EC2010010153 A EC 2010010153A EC SP10010153 A ECSP10010153 A EC SP10010153A EC SP10010153 A ECSP10010153 A EC SP10010153A
- Authority
- EC
- Ecuador
- Prior art keywords
- pharmaceutical compositions
- compositions containing
- bradiquinine
- antagonists
- hialuronic acid
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000002253 acid Substances 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 2
- 201000008482 osteoarthritis Diseases 0.000 abstract 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 abstract 1
- 229940123765 Bradykinin B2 receptor antagonist Drugs 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000003359 bradykinin B2 receptor antagonist Substances 0.000 abstract 1
- 229920002674 hyaluronan Polymers 0.000 abstract 1
- 229960003160 hyaluronic acid Drugs 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
Se describen las composiciones farmacéuticas que contienen, como ingredientes activos, una mezcla de un polímero de ácido hialurónico con un antagonista del receptor de bradiquinina B2. Se ha comprobado que dichas composiciones son especialmente efectivas en el tratamiento de enfermedades articulares degenerativas tales como osteoartritis usando inyecciones intraarticulares.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT002225A ITMI20072225A1 (it) | 2007-11-23 | 2007-11-23 | "composizioni farmaceutiche a base di antagonisti della bradichinina ed acido ialuronico e loro uso" |
| PCT/EP2008/009451 WO2009065507A2 (en) | 2007-11-23 | 2008-11-10 | Pharmaceutical compositions containing bradykinin antagonists and hyaluronic acid, and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP10010153A true ECSP10010153A (es) | 2010-06-29 |
Family
ID=40314753
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2010010153A ECSP10010153A (es) | 2007-11-23 | 2010-05-05 | Composiciones farmacéuticas que contienen antagonistas de bradiquinina y ácido hialurónico y sus usos |
Country Status (40)
| Country | Link |
|---|---|
| US (1) | US9101627B2 (es) |
| EP (1) | EP2222275B1 (es) |
| JP (1) | JP5383695B2 (es) |
| KR (1) | KR101585868B1 (es) |
| CN (1) | CN101868225B (es) |
| AP (1) | AP2628A (es) |
| AR (1) | AR069407A1 (es) |
| AT (1) | ATE529096T1 (es) |
| AU (1) | AU2008328311B2 (es) |
| BR (1) | BRPI0820402A2 (es) |
| CA (1) | CA2706398C (es) |
| CL (1) | CL2008003475A1 (es) |
| CO (1) | CO6270301A2 (es) |
| CR (1) | CR11457A (es) |
| CY (1) | CY1112134T1 (es) |
| DK (1) | DK2222275T3 (es) |
| EA (1) | EA017626B1 (es) |
| EC (1) | ECSP10010153A (es) |
| ES (1) | ES2374861T3 (es) |
| GE (1) | GEP20125602B (es) |
| HN (1) | HN2010001037A (es) |
| HR (1) | HRP20110904T1 (es) |
| IL (1) | IL205860A (es) |
| IT (1) | ITMI20072225A1 (es) |
| MA (1) | MA31913B1 (es) |
| MX (1) | MX2010005484A (es) |
| MY (1) | MY148685A (es) |
| NI (1) | NI201000087A (es) |
| NZ (1) | NZ585514A (es) |
| PA (1) | PA8804801A1 (es) |
| PE (1) | PE20091422A1 (es) |
| PL (1) | PL2222275T3 (es) |
| PT (1) | PT2222275E (es) |
| RS (1) | RS52045B (es) |
| SI (1) | SI2222275T1 (es) |
| TN (1) | TN2010000215A1 (es) |
| TW (1) | TWI448292B (es) |
| UA (1) | UA97867C2 (es) |
| WO (1) | WO2009065507A2 (es) |
| ZA (1) | ZA201003586B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RO131947A2 (ro) * | 2014-05-30 | 2017-06-30 | Nataliia Mykolaivna Derkach | Soluţie stabilizată bazată pe substanţe active, şi metodă de preparare a soluţiei stabilizate de substanţe active |
| CA2972212C (en) | 2014-12-26 | 2024-10-29 | Seikagaku Corporation | AGENT AND IMPROVEMENT OF SUBJECTIVE OCULAR SYMPTOMS AND ASSOCIATED METHOD |
| MX2020009824A (es) | 2018-07-25 | 2021-01-15 | Alteogen Inc | Nuevas variantes de hialuronidasa y composicion farmaceutica que comprende la misma. |
| CN112203642B (zh) | 2019-03-25 | 2025-03-07 | 阿特根公司 | 用于皮下注射的包含人透明质酸酶ph20变体和药物的药物组合物 |
| TW202615652A (zh) | 2020-01-23 | 2026-04-16 | 南韓商阿特根公司 | 新穎的具有改善的穩定性的玻尿酸酶變異體及含有其的醫藥組合物 |
| US11401303B2 (en) * | 2020-06-15 | 2022-08-02 | Taian City Qihang Biotechnology Co. | Synthetic peptide BRAP and application in preparation of anti-inflammatory drug for COVID-19 thereof |
| WO2022031093A1 (ko) | 2020-08-07 | 2022-02-10 | (주)알테오젠 | 재조합 히알루로니다제의 생산 방법 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7635489B2 (en) * | 2001-05-18 | 2009-12-22 | Leneau Holdings, Llc | Ingestion of hyaluronic acid for improved joint health |
| ITMI20021247A1 (it) * | 2002-06-07 | 2003-12-09 | Menarini Ricerche Spa | Antagonisti basici non peptidici della bradichinina e loro impiego informulazioni farmaceutiche |
| ITMI20041963A1 (it) | 2004-10-15 | 2005-01-15 | Luso Farmaco Inst | "antagonisti non-peptidici della bradichinina e loro composizioni farmaceutiche" |
-
2007
- 2007-11-23 IT IT002225A patent/ITMI20072225A1/it unknown
-
2008
- 2008-11-07 TW TW097142981A patent/TWI448292B/zh not_active IP Right Cessation
- 2008-11-10 MY MYPI2010002358A patent/MY148685A/en unknown
- 2008-11-10 EP EP08853047A patent/EP2222275B1/en active Active
- 2008-11-10 ES ES08853047T patent/ES2374861T3/es active Active
- 2008-11-10 EA EA201000678A patent/EA017626B1/ru not_active IP Right Cessation
- 2008-11-10 US US12/743,891 patent/US9101627B2/en not_active Expired - Fee Related
- 2008-11-10 DK DK08853047.2T patent/DK2222275T3/da active
- 2008-11-10 CN CN2008801169202A patent/CN101868225B/zh not_active Expired - Fee Related
- 2008-11-10 WO PCT/EP2008/009451 patent/WO2009065507A2/en not_active Ceased
- 2008-11-10 HR HR20110904T patent/HRP20110904T1/hr unknown
- 2008-11-10 PT PT08853047T patent/PT2222275E/pt unknown
- 2008-11-10 MX MX2010005484A patent/MX2010005484A/es active IP Right Grant
- 2008-11-10 NZ NZ585514A patent/NZ585514A/en not_active IP Right Cessation
- 2008-11-10 JP JP2010534395A patent/JP5383695B2/ja not_active Expired - Fee Related
- 2008-11-10 AP AP2010005265A patent/AP2628A/xx active
- 2008-11-10 SI SI200830475T patent/SI2222275T1/sl unknown
- 2008-11-10 BR BRPI0820402-0A patent/BRPI0820402A2/pt not_active IP Right Cessation
- 2008-11-10 UA UAA201006127A patent/UA97867C2/ru unknown
- 2008-11-10 GE GEAP200811807A patent/GEP20125602B/en unknown
- 2008-11-10 AU AU2008328311A patent/AU2008328311B2/en not_active Ceased
- 2008-11-10 RS RS20110524A patent/RS52045B/sr unknown
- 2008-11-10 CA CA2706398A patent/CA2706398C/en not_active Expired - Fee Related
- 2008-11-10 AT AT08853047T patent/ATE529096T1/de active
- 2008-11-10 PL PL08853047T patent/PL2222275T3/pl unknown
- 2008-11-10 KR KR1020107011164A patent/KR101585868B1/ko not_active Expired - Fee Related
- 2008-11-19 PE PE2008001955A patent/PE20091422A1/es not_active Application Discontinuation
- 2008-11-21 CL CL2008003475A patent/CL2008003475A1/es unknown
- 2008-11-21 AR ARP080105077A patent/AR069407A1/es unknown
- 2008-11-21 PA PA20088804801A patent/PA8804801A1/es unknown
-
2010
- 2010-05-05 EC EC2010010153A patent/ECSP10010153A/es unknown
- 2010-05-06 CO CO10054082A patent/CO6270301A2/es active IP Right Grant
- 2010-05-14 TN TN2010000215A patent/TN2010000215A1/fr unknown
- 2010-05-19 NI NI201000087A patent/NI201000087A/es unknown
- 2010-05-20 HN HN2010001037A patent/HN2010001037A/es unknown
- 2010-05-20 ZA ZA2010/03586A patent/ZA201003586B/en unknown
- 2010-05-20 IL IL205860A patent/IL205860A/en not_active IP Right Cessation
- 2010-05-21 CR CR11457A patent/CR11457A/es unknown
- 2010-06-15 MA MA32913A patent/MA31913B1/fr unknown
-
2011
- 2011-11-30 CY CY20111101177T patent/CY1112134T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6771417A2 (es) | Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis | |
| CO6270301A2 (es) | Composiciones farmaceuticas que contienen antagonistas de bradiquinina y acido hialuronico y sus usos | |
| EA201100691A1 (ru) | Антагонисты рецепторов лизофосфатидной кислоты | |
| BR112018004536A2 (pt) | peptídeos de endereçamento à cartilagem | |
| UY32926A (es) | Compuestos como antagonistas de los receptores de ácido lisofosfatídico | |
| EA201590590A1 (ru) | Модуляторы рецептора андрогенов и их применение | |
| IN2012DN02702A (es) | ||
| IN2012DN00754A (es) | ||
| CL2011000668A1 (es) | Compuestos derivados de pirazolopiridina; proceso de preparacion; composicion farmaceutica y uso en el tratamiento de enfermedades tales como artritis reumatoide, psoriasis, esclerosis multiple, entre otras. | |
| BR112014012789A2 (pt) | agentes terapêuticos compreendendo sequências de aminoácidos de insulina | |
| MX357496B (es) | Moduladores del receptor de estrógenos fluorados y sus usos. | |
| BR112014027981A2 (pt) | compostos do tipo fumagilol e métodos de produção e utilização dos mesmos | |
| WO2017093810A3 (en) | Composition for intraoral delivery of biologically active peptides and proteins | |
| MX2019011545A (es) | Composiciones celulares y de andamio inyectables. | |
| CL2009001006A1 (es) | Compuestos derivados del acido 4-dimetil-aminobutirico; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento o profilaxis de enfermedades tales como hiperglucemia, diabetes e hipertension entre otras. | |
| EP2547203A4 (en) | CCR5 MODULATORS TO TREAT HIV | |
| ECSP15005163A (es) | Composiciones líquidas orales pediátricas que contienen nepadutant | |
| ECSP11010752A (es) | Composiciones farmacéuticas basadas en antagonistas del receptor de quinina b2 y corticosteroides | |
| UY32679A (es) | Antagonistas policíclicos de receptores de ácido lisofosfatidico | |
| MX380487B (es) | Fructanos de agave como excipiente farmacéutico funcional en una forma de dosificación de liberación inmediata. | |
| EA200900172A1 (ru) | Фармацевтическая композиция для контрацепции | |
| UY36556A (es) | Nuevas composiciones farmacéuticas para el tratamiento de la hipertensión | |
| CL2011002316A1 (es) | Compuestos derivados de furopirimidinona, moduladores de receptores trpa1; composicion farmaceutica; y uso en el tratamiento del dolor. |